For Pharmaceutical and Life Sciences
Cognitive Sovereignty Checklist for Pharmaceutical and Life Sciences
AI tools like Schrödinger, Insilico Medicine, and BenevolentAI are now embedded in drug discovery pipelines, yet many researchers cannot explain why the system ranked Compound A above Compound B. Your organisation faces a real risk: scientific judgement atrophying as humans outsource critical thinking to black-box models, and patient safety concerns when trial designs are optimised by algorithms rather than evaluated by experienced clinicians.
These are suggestions. Take what fits, leave the rest.
0 / 20 applicable
Tap once to check, again to mark N/A, again to reset.
Protect Your Researchers' Foundational Knowledge
Document the chemistry or biology your team knew before using AIbeginner
Before deploying a tool like Schrödinger for lead optimisation, have each researcher write down their working hypotheses about what makes a compound bind well. Compare this to what the AI recommends. This keeps tacit knowledge visible and prevents it from disappearing.
Require researchers to predict results before running AI analysisbeginner
In drug discovery meetings, ask chemists to forecast which scaffolds will show activity, then run the AI model. When predictions differ from AI output, investigate why. This practice stops researchers from treating AI predictions as truth rather than hypotheses to test.
Rotate junior scientists away from AI-heavy work for hands-on wet lab timeintermediate
A postdoc who spends 18 months optimising compounds using only AI will not develop the synthetic intuition they need for independent work. Ensure rotation through bench chemistry, cell-based assays, or in vivo studies so they build real experimental judgement.
Audit whether your researchers can explain AI recommendations in biological termsintermediate
In one-on-one conversations, ask your lead chemist or biologist why the AI suggested a particular modification. If they cannot describe the mechanism in their own words, they are relying on the model rather than understanding it. This signals knowledge debt.
Host monthly journal clubs focused on methods papers, not just resultsintermediate
Many AI papers in drug discovery skip mechanistic details. Deliberately discuss papers on medicinal chemistry principles, pharmacokinetics, or assay design to keep foundational thinking alive and to train researchers to spot when AI claims go beyond what biology actually supports.
Create a 'black box register' documenting which tools your team cannot interrogateadvanced
List every AI tool in use (ChatGPT for regulatory writing, IBM Watson for target selection, BenevolentAI for knowledge graphs) and mark whether you can request model weights, feature importance, or training data. This accountability prevents silent knowledge loss.
Maintain Scientific Judgement in Trial Design and Endpoints
Review AI-suggested trial designs with experienced clinical leaders outside your AI teambeginner
When algorithms like those in Insilico Medicine optimise patient inclusion criteria or endpoint selection, have clinicians with 15+ years of experience challenge the output. They may catch that the model missed a patient-relevant endpoint or created cohorts too narrow for real-world use.
Document why you chose your primary endpoint before consulting any optimisation toolbeginner
Write down your clinical and regulatory rationale for the primary outcome first. Then run AI-based trial design optimisation. If the algorithm suggests a different endpoint, you are comparing reasoning to reasoning, not opinion to algorithm.
Run at least one trial arm using a traditional design to benchmark AI recommendationsintermediate
If AI suggests a novel adaptive design with predictive biomarker gates, run a parallel fixed cohort using conventional criteria. This gives you real data on whether the AI-driven approach actually reduces sample size or improves patient selection versus simply looking clever.
Separate the team that designs trials from the team that runs AI optimisationintermediate
Cognitive capture happens when the same people who chose to use an AI tool are the ones defending its outputs. Have your Clinical Operations or Medical Affairs team independently review any trial design changes that AI recommends.
Create a mandatory questioning checklist for all AI-generated trial amendmentsintermediate
Before submitting a Protocol Amendment to regulators, ask: Does this change make sense to a clinician who has never seen the AI model? Would we have made this change if we had designed the trial manually? Does it serve patient safety or company efficiency? Document answers.
Request the confidence intervals and sensitivity analyses behind any AI trial recommendationadvanced
Do not accept a single point estimate from a trial optimisation tool. Ask for uncertainty bounds, what happens if key assumptions shift, and whether the recommendation holds across patient subgroups. If the vendor cannot provide this, treat the output as exploratory only.
Audit whether endpoint selection has drifted toward what is easy to measure rather than clinically importantadvanced
AI tools optimise for statistical power and feasibility. Over time, teams may drop hard endpoints (mortality, hospitalisation) for biomarker endpoints because algorithms make them easier to detect. Review your trial portfolio annually to ensure endpoints still reflect what patients and regulators care about.
Build Critical Review Capacity for AI in Regulatory Submissions
Identify every section of your regulatory dossier that contains AI-generated or AI-analysed contentbeginner
ChatGPT summaries of literature, machine learning models for population pharmacokinetics, AI-written clinical summaries, or predictive analytics for safety: mark them all. Regulators like EMA and FDA cannot yet evaluate AI methodology, so you must do it first.
Train your Regulatory Affairs team to ask 'how would we know if this is wrong' about AI contentbeginner
When an AI tool generates a summary of drug-drug interactions or a literature synthesis for your Common Technical Document, challenge it with concrete questions: Which papers did it miss? Does this conclusion hold if we weight recent data more heavily? This habit stops AI outputs from appearing authoritative by default.
Require a human-authored critique alongside any AI analysis in your submissionintermediate
If you include machine learning results for exposure-response modelling, also submit a section written by your pharmacometrician explaining what the model does well, what it assumes, and what it does not capture. This gives regulators a foothold for evaluation.
Do not use ChatGPT or similar tools to draft your benefit-risk assessmentintermediate
Large language models generate plausible-sounding balance sheets that can obscure real uncertainties. Your Clinical Overview and benefit-risk summary must reflect your team's actual clinical judgement, even if it takes longer to write.
Conduct a cross-functional review specifically to spot where AI has replaced human reasoningintermediate
Bring together your Head of Medical, Regulatory Director, and a statistician not involved in the submission. Ask them to flag any claims or analyses that rely entirely on AI without independent verification. This catches subtle cases where automation has silently displaced expertise.
Request the underlying code, model card, or technical report for any predictive model in your dossieradvanced
Before submitting AI-driven analyses (population PK models, safety signal detection, efficacy prediction), ensure you have technical documentation showing how the model was trained, validated, and tested. If the vendor will not provide this, you cannot defend the model to regulators.
Simulate what a regulator would ask about your AI methods and answer it in writingadvanced
The FDA and EMA have published questions on AI/ML in drug development. For every AI-dependent section of your dossier, write a regulator-style question and your answer. This discipline surfaces gaps before submission and demonstrates your team understands the methodology.
Five things worth remembering
- When Insilico Medicine or BenevolentAI identifies a new target, have your biology team replicate the finding using orthogonal methods before committing resources. AI can identify statistical correlations that do not reflect biology.
- In trial design meetings, ask 'What would change our minds about this endpoint?' If the answer is 'only if the trial fails', the endpoint is not a hypothesis but a wish. AI can disguise this by making weak choices sound optimised.
- Require your Chemistry or Biology lead to maintain a notebook documenting when AI recommendations conflicted with their intuition and what happened. This record prevents knowledge loss and reveals where the AI is systematically weak.
- Do not let your Regulatory team copy-paste AI summaries into the Common Technical Document without reading them first. Regulators scrutinise AI-suspicious language, and sloppy automation damages credibility.
- Before licensing or acquiring an AI platform, negotiate for access to training data provenance, model validation reports, and a contact for technical questions. 'Black box' terms mean your team loses control over the science.
Related reads
Common questions
Should pharmaceutical and life sciencess document the chemistry or biology your team knew before using ai?
Before deploying a tool like Schrödinger for lead optimisation, have each researcher write down their working hypotheses about what makes a compound bind well. Compare this to what the AI recommends. This keeps tacit knowledge visible and prevents it from disappearing.
Should pharmaceutical and life sciencess require researchers to predict results before running ai analysis?
In drug discovery meetings, ask chemists to forecast which scaffolds will show activity, then run the AI model. When predictions differ from AI output, investigate why. This practice stops researchers from treating AI predictions as truth rather than hypotheses to test.
Should pharmaceutical and life sciencess rotate junior scientists away from ai-heavy work for hands-on wet lab time?
A postdoc who spends 18 months optimising compounds using only AI will not develop the synthetic intuition they need for independent work. Ensure rotation through bench chemistry, cell-based assays, or in vivo studies so they build real experimental judgement.